Neuphoria Therapeutics (NASDAQ:NEUP) Issues Quarterly Earnings Results, Misses Expectations By $4.53 EPS

Neuphoria Therapeutics (NASDAQ:NEUP) released its quarterly earnings results on Monday. The company reported ($5.79) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.26) by ($4.53), Zacks reports.

Neuphoria Therapeutics Price Performance

NEUP traded down $0.45 during trading on Monday, hitting $11.86. The stock had a trading volume of 49,390 shares, compared to its average volume of 212,071. Neuphoria Therapeutics has a twelve month low of $2.12 and a twelve month high of $15.14. The stock has a 50 day simple moving average of $9.72 and a two-hundred day simple moving average of $7.28.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on NEUP shares. Maxim Group raised their target price on Neuphoria Therapeutics from $18.00 to $35.00 and gave the stock a “buy” rating in a research note on Thursday, September 11th. HC Wainwright reissued a “buy” rating and issued a $21.00 price target on shares of Neuphoria Therapeutics in a research report on Tuesday, August 26th. Finally, Wall Street Zen upgraded shares of Neuphoria Therapeutics to a “hold” rating in a report on Saturday, July 26th. Two investment analysts have rated the stock with a Buy rating, According to MarketBeat.com, the company currently has a consensus rating of “Buy” and an average target price of $28.00.

Neuphoria Therapeutics Company Profile

Neuphoria Therapeutics, Inc is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor.